Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes

Internal Medicine

Volumn 48, Issue 6, 2009, Pages 401-409

  Tanabe, Naohito ^a   Saito, Kimie ^b   Yamada, Yukio ^c,d   Takasawa, Tetsuya ^c   Seki, Nao ^b   Suzuki, Hiroshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Shinrakuen Hospital   (Japan)

^d Niigata Pref Health Service Center   (Japan)

Author keywords

Diabetes mellitus; Insulin; Oral glucose tolerance test; Risk assessment

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DATA ANALYSIS; DIABETOGENESIS; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT IDENTIFICATION; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; MORBIDITY; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; URBAN POPULATION; YOUNG ADULT;

EID: 67650079007     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1325     Document Type: Article

References (16)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
2. Fang J, Alderman MH. Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes 55: 768-773, 2006.
3. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.
4. Kahn CR. Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43: 1066-1084, 1994.
5. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 137: 959-965, 1993.
6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
7. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
8. Seltzer HS, Allen EW, Herron AL Jr., Brennan MT. Insulin secretion in response to glycemic stimulus: Relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46: 323-335, 1967.
9. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 30: 1544-1548, 2007.
10. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151: 190-198, 2000.
11. Lyssenko V, Almgren P, Anevski D, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54: 166-174, 2005.
12. Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: Effects of lifestyle intervention and metformin. Diabetes 54: 2404-2414, 2005.
13. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55: 65-85, 2002.
14. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
15. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.
16. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 44: 406-413, 2004.